| |
| |
|
| Insider
Information: |
Collins Helen Louise |
| Relationship: |
|
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
0 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Five Prime Therapeutics Inc |
FPRX |
EVP and Chief Medical ... |
2021-04-16 |
0 |
|
0 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-04-11 |
0 |
2024-04-11 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF MEDICAL OFFICER |
• – – |
2024-04-11 |
4 |
AS |
$25.07 |
$501,478 |
D/D |
(20,000) |
0 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
CHIEF MEDICAL OFFICER |
• – – |
2024-04-11 |
4 |
OE |
$2.48 |
$49,600 |
D/D |
20,000 |
20,000 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-04-16 |
4 |
D |
$38.00 |
$5,150,786 |
D/D |
(135,547) |
0 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
66,000 |
135,547 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-03-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
8,085 |
69,547 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-02-26 |
4 |
D |
$22.23 |
$25,742 |
D/D |
(1,158) |
77,632 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-02-25 |
4 |
D |
$23.08 |
$38,151 |
D/D |
(1,653) |
78,790 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2021-02-24 |
4 |
D |
$25.71 |
$130,890 |
D/D |
(5,091) |
80,443 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-12-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,000 |
97,117 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-12-11 |
4 |
D |
$16.14 |
$186,950 |
D/D |
(11,583) |
85,534 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-11-11 |
4 |
D |
$18.00 |
$198,702 |
D/D |
(11,039) |
75,117 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-11-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,000 |
86,156 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-08-20 |
4 |
D |
$4.69 |
$3,879 |
D/D |
(827) |
64,156 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-03-20 |
4 |
D |
$2.30 |
$1,902 |
D/D |
(827) |
64,983 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-02-26 |
4 |
D |
$4.83 |
$6,187 |
D/D |
(1,281) |
65,810 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-02-25 |
4 |
D |
$4.87 |
$9,068 |
D/D |
(1,862) |
67,091 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
68,953 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2020-02-05 |
4 |
D |
$5.13 |
$27,420 |
D/D |
(5,345) |
38,953 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2019-09-01 |
4 |
D |
$5.43 |
$2,693 |
D/D |
(496) |
44,298 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
EVP and Chief Medical Officer |
• – – |
2019-08-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
44,794 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
SVP and Chief Medical Officer |
• – – |
2019-02-26 |
4 |
D |
$11.95 |
$14,065 |
D/D |
(1,177) |
39,794 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
SVP and Chief Medical Officer |
• – – |
2019-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
40,971 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
SVP and Chief Medical Officer |
• – – |
2019-02-05 |
4 |
D |
$11.43 |
$36,530 |
D/D |
(3,196) |
30,971 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
SVP and Chief Medical Officer |
• – – |
2018-09-28 |
4 |
D |
$13.92 |
$26,532 |
D/D |
(1,906) |
34,167 |
0 |
- |
|
| FPRX |
Five Prime Therapeutics I... |
SVP and Chief Medical Officer |
• – – |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,844 |
36,073 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
